Feb 06, 2017 06:01 am UTC| Business
In the Phase II TITAN study, treatment with caplacizumab significantly reduced the time to platelet count normalisation and the number of recurrences of aTTP while on drug treatment Post-hoc analysis of the TITAN study...
INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab
Feb 06, 2017 06:01 am UTC| Business
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia The study did not meet the primary efficacy endpoint...
Feb 06, 2017 06:00 am UTC| Business
Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter and full year 2016 results on...
Feb 06, 2017 06:00 am UTC| Business
LOS ANGELES, Feb. 05, 2017 -- Oracle (NYSE:ORCL) and Apollo Enterprise Solutions, Ltd. (“AES” or “The Company”) (AES:BH) (OAL:GR), a Gold level member of the Oracle PartnerNetwork, have achieved Oracle Validated...
Genmab Announces Updated 2016 Financial Guidance
Feb 06, 2017 05:40 am UTC| Business
Company Announcement Copenhagen, Denmark; February 6, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has updated its 2016 Financial Guidance. Based on preliminary reporting, Genmab is improving its...

Staying politically neutral is more dangerous for companies than you think
Feb 06, 2017 05:22 am UTC| Insights & Views Business Politics
President Donald Trumps executive order temporarily banning immigration from seven Muslim countries has put corporate executives in a bind. Almost from the moment he announced the ban, questions poured in about where those...
Feb 06, 2017 02:14 am UTC| Business
VANCOUVER, British Columbia, Feb. 05, 2017 -- B2Gold Corp. (TSX:BTO) (NYSE MKT:BTG) (NSX:B2G) (“B2Gold” or the “Company”) is pleased to announce fourth quarter and full-year 2016 gold production and revenue as well as...